|
6 January 2021 |
|
AIM: RENE.L |
RNS REACH
ReNeuron Group plc
("ReNeuron" or the "Company")
Analyst Conference Call
ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics, will host a conference call for analysts at 10.00am GMT today to discuss the Company's recent half year results, fundraising and outlook for the year ahead.
Analysts who require dial-in details, please contact Buchanan at reneuron@buchanan.uk.com.
A recorded webcast of the analyst conference call, including investor presentation slides, will be made available during the afternoon of 6 January 2021 at this link:
https://webcasting.buchanan.uk.com/broadcast/5fd23c59ca22cd76f9d3c662
The recorded webcast will also be made available at the investor centre of ReNeuron's website, http://www.reneuron.com/investors/investor-centre/.
ENQUIRIES:
|
ReNeuron |
+44 (0) 20 3819 8400 |
|
Olav Hellebø, Chief Executive Officer |
|
|
Michael Hunt, Chief Financial Officer |
|
|
Buchanan (UK Media/Investor relations) |
+44 (0) 20 7466 5000 |
|
Mark Court, Sophie Wills, Tilly Abraham |
|
|
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) Ben Maddison, Stewart Wallace |
+44 (0) 20 7710 7600 |
|
|
|
|
N+1 Singer (Joint Broker) Aubrey Powell, James Moat, Hannah Woodley |
+44 (0) 20 7496 3000 |
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
